Skip to main content
    N

    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.54
    -0.37 (-7.54%)

    Market Cap: $141.66M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    NeOnc Technologies Holdings, Inc. Common Stock (NTHI) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to NeOnc Technologies Holdings, Inc. Common Stock are OnKure Therapeutics (OKUR), Champions Oncology (CSBR) and Immuneering (IMRX). By market cap, NeOnc Technologies Holdings, Inc. Common Stock ranks 3rd of the 13 companies on this page; Immuneering (IMRX) is the largest at $240.27M.

    Peer Comparison

    NTHI's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    OnKure Therapeutics, Inc. (OKUR)$108.33MN/AN/A0.0%N/A0.0%0.00%
    Champions Oncology Inc (CSBR)$65.49MN/A1.0x-1.9%N/A8.8%0.00%
    Immuneering Corp (IMRX)$240.27MN/AN/A0.0%N/A-99.8%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Immunic Inc (IMUX)$102.61MN/AN/A0.0%N/A0.0%0.00%
    Sionna Therapeutics, Inc. Common Stock (SION)$150.63MN/AN/A0.0%N/A0.0%0.00%
    Oncolytics Biotech Inc (ONCY)$48.51MN/AN/A0.0%N/A0.0%0.00%
    OUTLOOK THERAPEUTICS INC (OTLK)$100.54MN/AN/A0.0%-776.9%-99.4%0.00%
    Minerva Neurosciences Inc (NERV)$114.62MN/AN/A0.0%N/A0.0%0.00%
    NRX Pharmaceuticals Inc (NRXP)$95.58MN/A23.8x0.0%N/A0.0%0.00%
    TuHURA Biosciences Inc (HURA)$88.58MN/AN/A0.0%-81.8%0.0%0.00%
    Nkarta Inc (NKTX)$85.23MN/AN/A0.0%N/A0.0%0.00%
    Peer median$101.58MN/A9.7x0.0%-429.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to NeOnc Technologies Holdings, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    OnKure Therapeutics, Inc. (OKUR)
    OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer.
    OKUR competitors
    Champions Oncology Inc (CSBR)
    Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States.
    CSBR competitors
    Immuneering Corp (IMRX)
    Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its...
    IMRX competitors
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors
    Immunic Inc (IMUX)
    Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune...
    IMUX competitors
    Sionna Therapeutics, Inc. Common Stock (SION)
    Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders...
    SION competitors
    Oncolytics Biotech Inc (ONCY)
    Oncolytics Biotech Inc., a developing-stage biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of cancer.
    ONCY competitors
    OUTLOOK THERAPEUTICS INC (OTLK)
    Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic...
    OTLK competitors
    Minerva Neurosciences Inc (NERV)
    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products...
    NERV competitors
    NRX Pharmaceuticals Inc (NRXP)
    NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company...
    NRXP competitors
    TuHURA Biosciences Inc (HURA)
    TuHURA Biosciences Inc is a pioneering biotechnology firm committed to advancing immunotherapy solutions for cancer and autoimmune diseases.
    HURA competitors
    Nkarta Inc (NKTX)
    Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer.
    NKTX competitors

    Frequently Asked Questions About NTHI

    Who are NeOnc Technologies Holdings, Inc. Common Stock's main competitors?

    The companies most similar to NeOnc Technologies Holdings, Inc. Common Stock include OnKure Therapeutics (OKUR), Champions Oncology (CSBR), Immuneering (IMRX), LENZ Therapeutics (LENZ) and Immunic (IMUX), listed from the closest match.

    Who is NeOnc Technologies Holdings, Inc. Common Stock's biggest competitor?

    Immuneering (IMRX) is the largest of the similar companies at $240.27M; OnKure Therapeutics (OKUR) is the closest match by business profile, size, sector and industry.

    How does NTHI stock compare with its competitors?

    NTHI's net margin is 0.0% against a peer median of 0.0%.

    Which of NeOnc Technologies Holdings, Inc. Common Stock's competitors pays a higher dividend?

    NeOnc Technologies Holdings, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is NeOnc Technologies Holdings, Inc. Common Stock bigger than its competitors?

    No. NeOnc Technologies Holdings, Inc. Common Stock is 3rd by market cap among the 13 companies on this page; the largest is Immuneering (IMRX) at $240.27M.